Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-04-12 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司受邀參加永豐證券舉辦之線上法人說明會
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1795 美時) participating in an online investor presentation hosted by 永豐證券. It includes details such as the date, time, and purpose of the event, which is to explain the company's financial and operational status to institutional investors. The document does not contain actual financial data or detailed presentation content, but rather serves as a notification of the event. The length is short (643 characters), and it explicitly states that full financial and business information can be found elsewhere. Therefore, this document is best classified as an Investor Presentation (IP) announcement or notification rather than the presentation itself. However, since it is announcing the event and not the presentation materials, it fits the Investor Presentation (IP) category as it focuses on the event for investors.
2022-04-12 Chinese
本公司受邀參加元富證券舉辦之2022年台股企業日
Investor Presentation Classification · 85% confidence The document is a short announcement (650 characters) about the company participating in an investor presentation event organized by a securities firm. It includes details such as date, time, and format of the event, and mentions that the company will explain its financial and operational status to institutional investors. There is no actual financial data or detailed report content included. The document serves as a notice of an upcoming investor presentation rather than the presentation itself or a financial report. Therefore, it fits best under the category of Investor Presentation (IP). Given the brevity and nature of the document, confidence is high but not absolute since the full presentation content is not included here.
2022-04-12 Chinese
公告本公司董事會決議召開111年股東常會
AGM Information Classification · 100% confidence The document is a formal announcement from the company 1795 美時 regarding the board of directors' resolution to convene the 111th Annual General Meeting (AGM). It includes details such as the date and location of the AGM, the agenda items including reports, approvals, discussions, elections, and other matters to be addressed at the meeting. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notification of the AGM and its agenda. The document length is short (1162 characters), and it is clearly an announcement of the AGM meeting and agenda, not the AGM materials or the full annual report. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-04-12 Chinese
公告本公司董事辭任
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's board of directors, specifically the resignation of a director named Hirofumi Imai. It includes details such as the resignation date, reason, and impact on board composition. There is no financial data, report, or presentation content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2022-04-12 Chinese
111年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in shareholdings by insiders, including directors, managers, and other key personnel. It includes data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement of a report. The document is a detailed insider shareholding disclosure, which aligns with the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives (insider trades). The document length is sufficient and contains substantive data, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2022-04-11 Chinese
111年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by insiders and related parties of the company 美時化學製藥股份有限公司. It lists shareholdings of directors, independent directors, senior management, and major shareholders, including pledged shares and percentages. There is no financial performance data, no discussion of financial results, no meeting materials, no voting results, no legal proceedings, no capital changes, and no earnings information. The document is a disclosure of insider shareholdings and pledges, which corresponds to a Director's Dealing or insider share transaction report. Given the nature of the data focusing on insider holdings and pledges, the best fitting category is Director's Dealing (DIRS). The document length is 3657 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement of a report. Therefore, the classification is DIRS with high confidence.
2022-04-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.